Supporting the significance of TRPV1 in cancer pain, targeting TRPV1 with genetic and pharmacological approaches reduces pain in bone cancer [10,11], squamous cell carcinoma [12], and pancreatic cancer [13]. This evidence concerns the gene TRPV1 and pancreatic neoplasm.